ReviewExpert opinion on therapeutic targets2014
Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder.
Review in Expert opinion on therapeutic targets, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 56 citations in OpenAlex.
- Increased Brain Lactate During Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive Bipolar Disorder: A 3-T 1H-MRS Study.Journal of clinical psychopharmacology · 2017Trial
- Investigating neural impairments in psychotic disorders using electroencephalography and cortical spheroids.Translational psychiatry · 2026Article
- Differential effects of lithium on metabolic dysfunctions in astrocytes derived from bipolar disorder patients.Molecular psychiatry · 2025Article
- The Association Among Bipolar Disorder, Mitochondrial Dysfunction, and Reactive Oxygen Species.Biomolecules · 2025Review
- Mitochondrial Dysfunction as a Biomarker of Illness State in Bipolar Disorder: A Critical Review.Brain sciences · 2024Review
- Comparing the metabolic pathways of different clinical phases of bipolar disorder through metabolomics studies.Frontiers in psychiatry · 2023Article
- Potential Utility of Natural Products against Oxidative Stress in Animal Models of Multiple Sclerosis.Antioxidants (Basel, Switzerland) · 2022Review
- Metabolomic biomarkers related to non-suicidal self-injury in patients with bipolar disorder.BMC psychiatry · 2022Article
- The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment.Frontiers in psychiatry · 2021Review
- Targeting Mitochondrial Dysfunction for Bipolar Disorder.Current topics in behavioral neurosciences · 2021Review
- The Role of Mitonuclear Incompatibility in Bipolar Disorder Susceptibility and Resilience Against Environmental Stressors.Frontiers in genetics · 2021Review
- Concepts of Neuroinflammation and Their Relationship With Impaired Mitochondrial Functions in Bipolar Disorder.Frontiers in behavioral neuroscience · 2021Review
- Shared preventive factors associated with relapse after a response to electroconvulsive therapy in four major psychiatric disorders.Psychiatry and clinical neurosciences · 2019Article
- Interaction of the Psychiatric Risk GeneFrontiers in cellular neuroscience · 2019Article
- Opportunities and challenges in psychopharmacology .Dialogues in clinical neuroscience · 2019Review
- A Genome-Wide Search for Bipolar Disorder Risk Loci Modified by Mitochondrial Genome Variation.Molecular neuropsychiatry · 2018Article
- The Effects of Histone Deacetylase Inhibition on the Levels of Cerebral Cytokines in an Animal Model of Mania Induced by Dextroamphetamine.Molecular neurobiology · 2018Article
- SlgA, encoded by the homolog of the human schizophrenia-associated geneDisease models & mechanisms · 2017Article
- Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar disorder: evidence in support of mitochondrial dysfunction hypothesis.Molecular psychiatry · 2016Article
- Nucleus accumbens deep-brain stimulation efficacy in ACTH-pretreated rats: alterations in mitochondrial function relate to antidepressant-like effects.Translational psychiatry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionBipolar disorder (BPD) is a severe illness with few treatments available. Understanding BPD pathophysiology and identifying potential relevant targets could prove useful for developing new treatments. Remarkably, subtle impairments of mitochondrial function may play an important role in BPD pathophysiology. AREAS COVERED: This article focuses on human studies and reviews evidence of mitochondrial dysfunction in BPD as a promising target for the development of new, improved treatments. Mitochondria are crucial for energy production, generated mainly through the electron transport chain (ETC) and play an important role in regulating apoptosis and calcium (Ca²⁺) signaling as well as synaptic plasticity. Mitochondria move throughout the neurons to provide energy for intracellular signaling. Studies showed polymorphisms of mitochondria-related genes as risk factors for BPD. Postmortem studies in BPD also show decreased ETC activity/expression and increased nitrosative and oxidative stress (OxS) in patient brains. BPD has been also associated with increased OxS, Ca²⁺ dysregulation and increased proapoptotic signaling in peripheral blood. Neuroimaging studies consistently show decreased energy levels and pH in brains of BPD patients. EXPERT OPINION: Targeting mitochondrial function, and their role in energy metabolism, synaptic plasticity and cell survival, may be an important avenue for development of new mood-stabilizing agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.